Literature DB >> 30982320

Effect of Fc Fusion on Folding and Immunogenicity of Middle East Respiratory Syndrome Coronavirus Spike Protein.

Jungmin Chun1,2, Yeondong Cho1,2, Ki Hoon Park1,2, Hanul Choi1,2, Hansam Cho2, Hee-Jung Lee2, Hyun Jang3, Kyung Hyun Kim4, Yu-Kyoung Oh5, Young Bong Kim1,2.   

Abstract

Middle East respiratory syndrome coronavirus (MERS-CoV) induces severe respiratory impairment with a reported mortality rate of ~36% in humans. The absence of clinically available MERS-CoV vaccines and treatments to date has resulted in uncontrolled incidence and propagation of the virus. In vaccine design, fusion with the IgG Fc domain is reported to increase the immunogenicity of various vaccine antigens. However, limited reports have documented the potential negative effects of Fc fusion on vaccine antigens. To determine whether Fc fusion affects the immunogenicity of MERS-CoV antigen, we constructed a Fcassociated MERS-CoV spike protein (eS770-Fc, 110 kDa), whereby human IgG4 Fc domain was fused to MERS-CoV spike protein (eS770) via a Gly/Pro linker using baculovirus as the expression system. For comparative analyses, two eS770 proteins lacking the IgG4 Fc domain were generated using the IdeS protease (eS770-ΔFc) or His tag attachment (eS770-His) and the immunogenicity of the above constructs were examined following intramuscular immunization in mice. Contrary to expectations, non-Fc spike proteins (eS770-ΔFc, eS770-His; 90 kDa) showed higher immunogenicity than the Fc fusion protein (eS770-Fc). Moreover, unlike non- Fc spike proteins, eS770-Fc immunization did not elicit neutralizing antibodies against MERSCoV. The lower immunogenicity of Fc-fused eS770 was related to alterations in the structural conformation of the spike protein. Taken together, our results indicate that IgG Fc fusion reduces the immunogenicity of eS770 by interfering with the proper folding structure.

Entities:  

Keywords:  IgG Fc domain; MERS-CoV; immunogenicity; protein folding; subunit vaccine

Mesh:

Substances:

Year:  2019        PMID: 30982320     DOI: 10.4014/jmb.1903.03043

Source DB:  PubMed          Journal:  J Microbiol Biotechnol        ISSN: 1017-7825            Impact factor:   2.351


  3 in total

1.  Human endogenous retrovirus-enveloped baculoviral DNA vaccines against MERS-CoV and SARS-CoV2.

Authors:  Hansam Cho; Yuyeon Jang; Ki-Hoon Park; Hanul Choi; Aleksandra Nowakowska; Hee-Jung Lee; Minjee Kim; Min-Hee Kang; Jin-Hoi Kim; Ha Youn Shin; Yu-Kyoung Oh; Young Bong Kim
Journal:  NPJ Vaccines       Date:  2021-03-19       Impact factor: 7.344

2.  Functional Trimeric SARS-CoV-2 Envelope Protein Expressed in Stable CHO Cells.

Authors:  Patrick Mayrhofer; Monika Hunjadi; Renate Kunert
Journal:  Front Bioeng Biotechnol       Date:  2021-12-17

3.  Codelivery of improved immune complex and virus-like particle vaccines containing Zika virus envelope domain III synergistically enhances immunogenicity.

Authors:  Andrew G Diamos; Mary D Pardhe; Haiyan Sun; Joseph G L Hunter; Tsafrir Mor; Lydia Meador; Jacquelyn Kilbourne; Qiang Chen; Hugh S Mason
Journal:  Vaccine       Date:  2020-03-12       Impact factor: 3.641

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.